Gabapentin Capsule
Product Images NDC 72789-055

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72789-055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

72789055 (72789055)

72789055 (72789055)
This is a description of Gabapentin, a medicine in capsule form with a strength of 300mg. Each bottle contains 180 capsules, with a lot number of F20C11 and an expiration date of 06/2022. The bottle also has a reorder number of 111087. Gabapentin may cause drowsiness, so it is advised to avoid alcohol while taking it as it can impair driving ability. Antacids must not be taken simultaneously. The bottle has warnings to keep it out of reach from children, and individuals experiencing side effects should consult their doctor or may report it to the FDA. The recommended dosage is not specified, but the label indicates that the capsule should be taken several times a day.*
FDA Label Image

1 (Image 1)

1 (Image 1)
This is a formula used to calculate estimated renal function in patients, by using the patient's age, weight, and serum creatinine level. The formula is specifically designed for adults and may not apply to children.*
FDA Label Image

Image 10

Image 10
FDA Label Image

Image 2

Image 2
FDA Label Image

1 (Image 5)

1 (Image 5)
FDA Label Image

1 (Image 6)

1 (Image 6)
The text describes the mean pain score after a dose titration period of 4 weeks, followed by a 4-week fixed dose period. The treatments being compared are a placebo and a daily dose of 3600 mg of gabapentin. The baseline is not specified but the data is reported over the course of weeks.*
FDA Label Image

2 (Image 7)

2 (Image 7)
This is a chart for a study related to pain management. It shows the mean pain score for different groups of individuals over a period of four weeks. The groups are divided based on the dosage of Gabapentin they were given, which were either 1800 mg/day or 2400 mg/day. The chart depicts that there was no significant difference in the mean pain score between the two groups during the four-week period.*
FDA Label Image

3 (Image 8)

3 (Image 8)
FDA Label Image

4 (Image 9)

4 (Image 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.